Review



cytofecttm huvec transfection kit  (Cell Applications Inc)


Bioz Verified Symbol Cell Applications Inc is a verified supplier
Bioz Manufacturer Symbol Cell Applications Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Cell Applications Inc cytofecttm huvec transfection kit
    Fig. 1 High glucose and TNFα induce a profound gene expression and phenotypic change. a <t>HUVECs</t> were treated in biological duplicates as Day 0: 25 mM mannitol as normal glucose and osmolarity control (NM); Day 3: combined treatment consisting 25 mM D-glucose and 5 ng/mL TNFα (H + T) for 3 days; and Day 7: H + T treatment for 7 days. Each group of treated cells was subjected to single-cell RNA-seq (scRNA-seq), Hi-C, and iMARGI assays. b t-SNE plot of scRNA-seq (4000–15,000 cells per sample) showed clear separation by treatment condition into three distinct clusters. c Principal component analysis of scRNA-seq data: single cells are plotted in the first two PC space and are labeled in red (Day 0, i.e., NM), green (Day 3, i.e., 3-day H + T treatment), and blue (Day 7, i.e., 7-day H + T treatment). d Expression heatmap (z-scaled) of top DE genes in single ECs grouped into functional pathways. Cells were ordered by increasing SERPINE1 expression (per each sample separately) and binned per 100 cells for the analysis. A total of 269 bins in Day 0, 177 bins in Day 3, and 148 bins in Day 7. e t-SNE plots of the expression level of selected genes in each single cell across the time course. The RNA levels are represented by log-normalized unique molecular identifier counts. f mRNA levels of eNOS and α-SMA in NM vs. H + T-treated HUVECs and cells untreated (NT) or treated with TGF-β (10 ng/mL) and IL-1β (5 ng/mL; T + I) for 3 or 7 days. The respective control was set as 1. Relative eNOS level: data represent mean ± SEM from five independent experiments; relative α-SMA level in H + T treatment: data represent mean ± SEM from seven independent experiments; relative α-SMA level in T + I treatment: data represent mean ± SEM from four independent experiments. *P = 0.0067, 0.0087, 0.0057, and 0.0017 from left to right based on ANOVA with Bonferroni as post hoc test. g Cell morphology under bright field (BF), immunofluorescent staining of α-SMA, and VE-cadherin (VE-cad), phalloidin staining of cytoskeleton, and DRAQ5 (DRAQ) staining of the nuclei. Representative images from five independent experiments are shown. Scale bar of BF = 100 µm; scale bars of (immuno)fluorescent staining = 50 µm. Source data are provided as a Source data file.
    Cytofecttm Huvec Transfection Kit, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 92/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/Cytofect+HUVEC+Transfection+Kit/pm33060583-245-6-10
    Average 92 stars, based on 5 article reviews
    cytofecttm huvec transfection kit - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Stress-induced RNA-chromatin interactions promote endothelial dysfunction."

    Article Title: Stress-induced RNA-chromatin interactions promote endothelial dysfunction.

    Journal: Nature communications

    doi: 10.1038/s41467-020-18957-w

    Fig. 1 High glucose and TNFα induce a profound gene expression and phenotypic change. a HUVECs were treated in biological duplicates as Day 0: 25 mM mannitol as normal glucose and osmolarity control (NM); Day 3: combined treatment consisting 25 mM D-glucose and 5 ng/mL TNFα (H + T) for 3 days; and Day 7: H + T treatment for 7 days. Each group of treated cells was subjected to single-cell RNA-seq (scRNA-seq), Hi-C, and iMARGI assays. b t-SNE plot of scRNA-seq (4000–15,000 cells per sample) showed clear separation by treatment condition into three distinct clusters. c Principal component analysis of scRNA-seq data: single cells are plotted in the first two PC space and are labeled in red (Day 0, i.e., NM), green (Day 3, i.e., 3-day H + T treatment), and blue (Day 7, i.e., 7-day H + T treatment). d Expression heatmap (z-scaled) of top DE genes in single ECs grouped into functional pathways. Cells were ordered by increasing SERPINE1 expression (per each sample separately) and binned per 100 cells for the analysis. A total of 269 bins in Day 0, 177 bins in Day 3, and 148 bins in Day 7. e t-SNE plots of the expression level of selected genes in each single cell across the time course. The RNA levels are represented by log-normalized unique molecular identifier counts. f mRNA levels of eNOS and α-SMA in NM vs. H + T-treated HUVECs and cells untreated (NT) or treated with TGF-β (10 ng/mL) and IL-1β (5 ng/mL; T + I) for 3 or 7 days. The respective control was set as 1. Relative eNOS level: data represent mean ± SEM from five independent experiments; relative α-SMA level in H + T treatment: data represent mean ± SEM from seven independent experiments; relative α-SMA level in T + I treatment: data represent mean ± SEM from four independent experiments. *P = 0.0067, 0.0087, 0.0057, and 0.0017 from left to right based on ANOVA with Bonferroni as post hoc test. g Cell morphology under bright field (BF), immunofluorescent staining of α-SMA, and VE-cadherin (VE-cad), phalloidin staining of cytoskeleton, and DRAQ5 (DRAQ) staining of the nuclei. Representative images from five independent experiments are shown. Scale bar of BF = 100 µm; scale bars of (immuno)fluorescent staining = 50 µm. Source data are provided as a Source data file.
    Figure Legend Snippet: Fig. 1 High glucose and TNFα induce a profound gene expression and phenotypic change. a HUVECs were treated in biological duplicates as Day 0: 25 mM mannitol as normal glucose and osmolarity control (NM); Day 3: combined treatment consisting 25 mM D-glucose and 5 ng/mL TNFα (H + T) for 3 days; and Day 7: H + T treatment for 7 days. Each group of treated cells was subjected to single-cell RNA-seq (scRNA-seq), Hi-C, and iMARGI assays. b t-SNE plot of scRNA-seq (4000–15,000 cells per sample) showed clear separation by treatment condition into three distinct clusters. c Principal component analysis of scRNA-seq data: single cells are plotted in the first two PC space and are labeled in red (Day 0, i.e., NM), green (Day 3, i.e., 3-day H + T treatment), and blue (Day 7, i.e., 7-day H + T treatment). d Expression heatmap (z-scaled) of top DE genes in single ECs grouped into functional pathways. Cells were ordered by increasing SERPINE1 expression (per each sample separately) and binned per 100 cells for the analysis. A total of 269 bins in Day 0, 177 bins in Day 3, and 148 bins in Day 7. e t-SNE plots of the expression level of selected genes in each single cell across the time course. The RNA levels are represented by log-normalized unique molecular identifier counts. f mRNA levels of eNOS and α-SMA in NM vs. H + T-treated HUVECs and cells untreated (NT) or treated with TGF-β (10 ng/mL) and IL-1β (5 ng/mL; T + I) for 3 or 7 days. The respective control was set as 1. Relative eNOS level: data represent mean ± SEM from five independent experiments; relative α-SMA level in H + T treatment: data represent mean ± SEM from seven independent experiments; relative α-SMA level in T + I treatment: data represent mean ± SEM from four independent experiments. *P = 0.0067, 0.0087, 0.0057, and 0.0017 from left to right based on ANOVA with Bonferroni as post hoc test. g Cell morphology under bright field (BF), immunofluorescent staining of α-SMA, and VE-cadherin (VE-cad), phalloidin staining of cytoskeleton, and DRAQ5 (DRAQ) staining of the nuclei. Representative images from five independent experiments are shown. Scale bar of BF = 100 µm; scale bars of (immuno)fluorescent staining = 50 µm. Source data are provided as a Source data file.

    Techniques Used: Gene Expression, Control, RNA Sequencing, Hi-C, Labeling, Expressing, Functional Assay, Staining

    Fig. 2 Overview of time-course Hi-C and iMARGI data. a, b Proportions of intrachromosomal (yellow) and interchromosomal read pairs (blue) in Hi-C (a) and iMARGI data (b) at the three time points (columns). c An example of interchromosomal iMARGI read pairs mapped to chromosome 2 near LINC00607 (left) and chromosome 7 near SERPINE1 (right). The RNA end (pink) and the DNA end (green) of each read pair is linked by a horizontal line. d Examples of overlapping iMARGI read pairs on a contact matrix from the RNA end (rows) to the DNA end (columns) with SEs (marked in light blue and in SE tracks) in control (Day 0) ECs. Genome region: chr1:75,000,0000–chr1:125,000,000. Resolution = 200 kb. e Proportions of iMARGI read pairs with the RNA ends (pink) or the DNA ends (green) in Day 0 (Ctrl) and Days 3 and 7 (H + T) ECs mapped to HUVEC SEs. Dotted line: the relative size of HUVEC SEs compared to the size of the genome. Source data are provided as a Source data file.
    Figure Legend Snippet: Fig. 2 Overview of time-course Hi-C and iMARGI data. a, b Proportions of intrachromosomal (yellow) and interchromosomal read pairs (blue) in Hi-C (a) and iMARGI data (b) at the three time points (columns). c An example of interchromosomal iMARGI read pairs mapped to chromosome 2 near LINC00607 (left) and chromosome 7 near SERPINE1 (right). The RNA end (pink) and the DNA end (green) of each read pair is linked by a horizontal line. d Examples of overlapping iMARGI read pairs on a contact matrix from the RNA end (rows) to the DNA end (columns) with SEs (marked in light blue and in SE tracks) in control (Day 0) ECs. Genome region: chr1:75,000,0000–chr1:125,000,000. Resolution = 200 kb. e Proportions of iMARGI read pairs with the RNA ends (pink) or the DNA ends (green) in Day 0 (Ctrl) and Days 3 and 7 (H + T) ECs mapped to HUVEC SEs. Dotted line: the relative size of HUVEC SEs compared to the size of the genome. Source data are provided as a Source data file.

    Techniques Used: Hi-C, Control

    Fig. 4 Inhibition of LINC00607 attenuates SERPINE1 induction and EC dysfunction. a Illustration of LINC00607 genomic locus and gene structure and LNA GapmeRs targeting of LINC00607 RNA. b HUVECs were transfected with scramble (scr) or two LNAs targeting LINC00607. LINC00607 RNA and SERPINE1 mRNA levels were quantified. Data represent mean ± SEM from seven independent experiments. c qPCR of LINC00607 in subcellular fractionations of HUVECs transfected with scr, LNA1, or LNA2. Data represent mean ± SEM from four independent experiments. d RNA-seq was performed with cells transfected as in b in biological replicates. Heatmap is plotted based on z-scaled log-transformed gene expression levels. e, f ECs transfected with scr or LNA1 and then treated by H + T were used in e monocyte adhesion assay and in f SA-β-gal assay. In e, the number of attached monocytes to ECs were quantified. Data represent mean ± SEM from eight independent experiments performed with peripheral blood-derived monocytes from four individual donors. Representative images show the attachment of fluorescently labeled peripheral blood-derived monocytes to ECs for experiments performed with monocytes from three different donors. In f, ECs with positive β-gal staining were quantified. The positively stained cell number in scr control was set to 100 (%). f Data represent mean ± SEM from four independent experiments respectively. Scale bar = 200 μm. * denotes p = 0.0289, 0.0013, 0.001, 0.0001, 0.0025, and 0.024 from left to right (in b) and p = 0.0023, 0.0079, and 0.0249 from left to right (in c) between indicated groups based on ANOVA followed by Bonferroni post hoc test (in b and c); p = 0.0039 (in e) and 0.0014 (in f), as compared to scr group based on two-tailed paired t test (in e and f). Source data are provided as a Source data file.
    Figure Legend Snippet: Fig. 4 Inhibition of LINC00607 attenuates SERPINE1 induction and EC dysfunction. a Illustration of LINC00607 genomic locus and gene structure and LNA GapmeRs targeting of LINC00607 RNA. b HUVECs were transfected with scramble (scr) or two LNAs targeting LINC00607. LINC00607 RNA and SERPINE1 mRNA levels were quantified. Data represent mean ± SEM from seven independent experiments. c qPCR of LINC00607 in subcellular fractionations of HUVECs transfected with scr, LNA1, or LNA2. Data represent mean ± SEM from four independent experiments. d RNA-seq was performed with cells transfected as in b in biological replicates. Heatmap is plotted based on z-scaled log-transformed gene expression levels. e, f ECs transfected with scr or LNA1 and then treated by H + T were used in e monocyte adhesion assay and in f SA-β-gal assay. In e, the number of attached monocytes to ECs were quantified. Data represent mean ± SEM from eight independent experiments performed with peripheral blood-derived monocytes from four individual donors. Representative images show the attachment of fluorescently labeled peripheral blood-derived monocytes to ECs for experiments performed with monocytes from three different donors. In f, ECs with positive β-gal staining were quantified. The positively stained cell number in scr control was set to 100 (%). f Data represent mean ± SEM from four independent experiments respectively. Scale bar = 200 μm. * denotes p = 0.0289, 0.0013, 0.001, 0.0001, 0.0025, and 0.024 from left to right (in b) and p = 0.0023, 0.0079, and 0.0249 from left to right (in c) between indicated groups based on ANOVA followed by Bonferroni post hoc test (in b and c); p = 0.0039 (in e) and 0.0014 (in f), as compared to scr group based on two-tailed paired t test (in e and f). Source data are provided as a Source data file.

    Techniques Used: Inhibition, Transfection, RNA Sequencing, Transformation Assay, Gene Expression, Cell Adhesion Assay, Derivative Assay, Labeling, Staining, Control, Two Tailed Test

    Related Articles

    Transfection:

    Article Title: Attenuation of indoxyl sulfate-induced cell damage by cinchonidine-a Cinchona alkaloid-through the downregulation of p53 signaling pathway by promoting MDM2 cytoplasmic-nuclear shuttling in endothelial cells.
    Article Snippet: Renocardiac syndromes are a critical concern among patients with chronic kidney disease (CKD).. High level of indoxyl sulfate (IS), a protein-bound uremic toxin, in plasma is known to promote the pathogenesis of cardiovascular diseases by impairing endothelial function.. However, the therapeutic effects of the adsorbent of indole, a precursor of IS, on renocardiac syndromes is still debated.

    Article Title: MicroRNA-494 Regulates Endoplasmic Reticulum Stress in Endothelial Cells
    Article Snippet: Specifically, siRNA for ATF6 (Cat: SR307883A, Origene), EIF2AK3 (Cat: SR306267A, Origene), ERN1 (Cat: SR301457A&B, Origene), BIRC5 (Cat: AM16708, Thermo Fisher), siRNA Negative Control (Cat: SR30001, Origene). .. For plasmid transfections, HUVECs were transfected using the Cytofect HUVECs transfection kit (Cat:TF200K, Cell Applications). pEGFP-ATF6 was a gift from Ron Prywes (Addgene plasmid # 32955) ( ). ..

    Article Title: Identifying Markers and Mechanisms of Atherosclerosis in Endothelial Cells Under Shear Stress Using High-Throughput Sequencing Data
    Article Snippet: .. Transfection of ECs with GFP-Cas9 with or without sgRNAs were performed with CytofectTM HUVEC transfection kit (Cell Applications). ..

    Article Title: Stress-induced RNA-chromatin interactions promote endothelial dysfunction.
    Article Snippet: .. Plasmid transfection was performed using the CytofectTM HUVEC Transfection kit (Cell Applications) following the manufacturer’s protocol in 6-well or 12-well plates. ..

    Article Title: Enhancer-associated long non-coding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function.
    Article Snippet: .. Transfection of ECs with GFP-Cas9 with or without sgRNAs was performed with Cytofect HUVEC transfection kit (Cell Applications). ..

    Plasmid Preparation:

    Article Title: Attenuation of indoxyl sulfate-induced cell damage by cinchonidine-a Cinchona alkaloid-through the downregulation of p53 signaling pathway by promoting MDM2 cytoplasmic-nuclear shuttling in endothelial cells.
    Article Snippet: Renocardiac syndromes are a critical concern among patients with chronic kidney disease (CKD).. High level of indoxyl sulfate (IS), a protein-bound uremic toxin, in plasma is known to promote the pathogenesis of cardiovascular diseases by impairing endothelial function.. However, the therapeutic effects of the adsorbent of indole, a precursor of IS, on renocardiac syndromes is still debated.

    Article Title: MicroRNA-494 Regulates Endoplasmic Reticulum Stress in Endothelial Cells
    Article Snippet: Specifically, siRNA for ATF6 (Cat: SR307883A, Origene), EIF2AK3 (Cat: SR306267A, Origene), ERN1 (Cat: SR301457A&B, Origene), BIRC5 (Cat: AM16708, Thermo Fisher), siRNA Negative Control (Cat: SR30001, Origene). .. For plasmid transfections, HUVECs were transfected using the Cytofect HUVECs transfection kit (Cat:TF200K, Cell Applications). pEGFP-ATF6 was a gift from Ron Prywes (Addgene plasmid # 32955) ( ). ..

    Article Title: Stress-induced RNA-chromatin interactions promote endothelial dysfunction.
    Article Snippet: .. Plasmid transfection was performed using the CytofectTM HUVEC Transfection kit (Cell Applications) following the manufacturer’s protocol in 6-well or 12-well plates. ..

    Luciferase:

    Article Title: Attenuation of indoxyl sulfate-induced cell damage by cinchonidine-a Cinchona alkaloid-through the downregulation of p53 signaling pathway by promoting MDM2 cytoplasmic-nuclear shuttling in endothelial cells.
    Article Snippet: Renocardiac syndromes are a critical concern among patients with chronic kidney disease (CKD).. High level of indoxyl sulfate (IS), a protein-bound uremic toxin, in plasma is known to promote the pathogenesis of cardiovascular diseases by impairing endothelial function.. However, the therapeutic effects of the adsorbent of indole, a precursor of IS, on renocardiac syndromes is still debated.



    Similar Products

    95
    PromoCell huvecs
    Huvecs, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/Human+Umbilical+Vein+Endothelial+Cells+(HUVEC)+pooled/10__1007_slash_s12195___026___00951___9-237-0-2
    Average 95 stars, based on 1 article reviews
    huvecs - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    huvec  (ATCC)
    96
    ATCC huvec
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Huvec, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/HUV-EC-C/pmc13670403-161-10-13
    Average 96 stars, based on 1 article reviews
    huvec - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    99
    ATCC human umbilical vein endothelial cell huvec
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Human Umbilical Vein Endothelial Cell Huvec, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human%2C+Pooled/10__1038_slash_s41467___026___78290___6-330-21-55
    Average 99 stars, based on 1 article reviews
    human umbilical vein endothelial cell huvec - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    ATCC culture conditions human umbilical vein endothelial cells huvecs
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Culture Conditions Human Umbilical Vein Endothelial Cells Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/RAW+264%2E7/pm42843050-49-3-18
    Average 99 stars, based on 1 article reviews
    culture conditions human umbilical vein endothelial cells huvecs - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    96
    ATCC huvec cell lines
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Huvec Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/HUV-EC-C/pm42832895-48-2-8
    Average 96 stars, based on 1 article reviews
    huvec cell lines - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    95
    PromoCell human umbilical vein endothelial cells huvecs
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Human Umbilical Vein Endothelial Cells Huvecs, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/Human+Umbilical+Vein+Endothelial+Cells+(HUVEC)+pooled/10__1186_slash_s13287___026___05262___4-74-0-9
    Average 95 stars, based on 1 article reviews
    human umbilical vein endothelial cells huvecs - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    huvecs  (ATCC)
    99
    ATCC huvecs
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pm42837752-163-0-2
    Average 99 stars, based on 1 article reviews
    huvecs - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    95
    PromoCell human umbilical vein endothelial cells
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Human Umbilical Vein Endothelial Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/Human+Umbilical+Vein+Endothelial+Cells+(HUVEC)+pooled/pm42801946-85-6-12
    Average 95 stars, based on 1 article reviews
    human umbilical vein endothelial cells - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    96
    ATCC huv ec c huvecs
    Cell viability graphs of studied cell lines <t>(A:</t> <t>DLD‐1;</t> B: HL‐60 and C: <t>HUVEC</t> cell lines).
    Huv Ec C Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/huvec/HUV-EC-C/pm42788740-299-3-9
    Average 96 stars, based on 1 article reviews
    huv ec c huvecs - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Cell viability graphs of studied cell lines (A: DLD‐1; B: HL‐60 and C: HUVEC cell lines).

    Journal: Chemistry & Biodiversity

    Article Title: Biological Activities and Phytochemical Composition of Arum rupicola var. rupicola : An In Vitro and In Silico Study

    doi: 10.1002/cbdv.71785

    Figure Lengend Snippet: Cell viability graphs of studied cell lines (A: DLD‐1; B: HL‐60 and C: HUVEC cell lines).

    Article Snippet: Cytotoxicity studies were conducted using DLD‐1 (colon carcinoma; ATCC CVCL_0248), HUVEC (normal endothelial; ATCC CCVL_2959), and HL‐60 (leukemia; ATCC CVCL_0002) cell lines.

    Techniques: